When scientists at the California-based pharmaceutical company, Immune Response, proposed changes to James Kahn's article on the failure of the company's experimental AIDS treatment, Kahn refused. The University of California at San Francisco (UCSF) researcher perceived the company's post-hoc analysis to be "spin." The company described it as good science. When Kahn submitted the study to the Journal of the American Medical Association, they immediately agreed to publish it, accompanied by separate articles on the perils of industry-sponsored research. The story quickly became front-page news.